Endowed Research Unit for Virological Medicine
[Social Contribution by Viral Vectors]

Institute of Industrial Science, Endowed Chairs

Virological Medicine

Sponsor: GCAT Co., LTD
Period: April 2022 to March 2024

Through the development of recombinant vaccines using genetically recombinant viruses, we will research and explore therapeutic medicines for incurable and unpreventable infectious diseases to advance translational research (TR).

We have previously successfully developed genetic recombinant vaccines using vectors such as the measles virus and canine distemper virus. The Nipah virus vaccine using the recombinant measles virus was recognized to be a promising vaccine and received large-scale support from the Coalition for Epidemic Preparedness Innovations (CEPI) for joint international research. Practical implementation and application of the world's first Nipah virus vaccine is expected.

We aim to further develop new innovative vaccines and drug development strategies for severe incurable and unpreventable diseases.

Through collaboration with researchers at The University of Tokyo as well as other domestic and international organizations, we would like to expand the globalization of the philosophy of The University of Tokyo.

Basic Research

Recombinant Virus

Drug/Treatment Development

Vaccine Development

Severe Infectious Diseases
Incurable and Unpreventable Diseases

Translational Research

Through the development of recombinant vaccines using genetically recombinant viruses, we will research and explore therapeutic medicines for incurable and unpreventable infectious diseases to advance translational research (TR).